Careers  |  Sign In  |  Register

Overview of Phase 2 Nivolumab, Ramucirumab Clinical Trial for Mesothelioma

Arkadiusz Z. Dudek, MD, medical oncologist at Regions Hospital Care Center in St. Paul, Minnesota, discusses a phase 2 trial of nivolumab plus ramucirumab in previously treated mesothelioma patients. This treatment regimen appears well tolerated, with few immune-related toxicities. Dr. Dudek notes that infusion time is short, requiring approximately 3 hours of total clinic time.

Faculty

D. Ross Camidge, MD, PhD
D. Ross Camidge, MD, PhD

Professor, Medicine - Medical Oncology

University of Colorado Cancer Center

Anschutz Medical Campus

Erin Schenk, MD, PhD
Erin Schenk, MD, PhD

Assistant Professor, Medicine - Medical Oncology

University of Colorado Cancer Center

Anschutz Medical Campus